ResultsIQ

ResultsIQ › Latest results › Alivus Life Sciences Limited

Alivus Life Sciences Limited Q1 FY26 results deck summary

NSE: ALIVUS · BSE: 543322

Results deck of 1 Aug 2025, summarised by AI from the filing.

GPL business de-grew 30.0% QoQ and 22.3% YoY to ₹1,526 mn on inventory rationalization at the customer's end.

Key takeaways

  1. Change GPL business de-grew 30.0% QoQ and 22.3% YoY to ₹1,526 mn on inventory rationalization at the customer's end.
  2. Risk Inventory rationalization by customers in North America, LATAM and GPL business reduced QoQ revenue.

Original filing on BSE

Alivus Life Sciences Limited Q1 FY27 results

As filed: Revenue ₹640 cr (+6% year on year), EBITDA ₹212 cr (+23% year on year), PAT ₹160 cr (+31% year on year), EBITDA margin 33.1% (+449 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹689 cr (+6% year on year), EBITDA ₹215 cr (+8% year on year), PAT ₹163 cr (+15% year on year), EBITDA margin 31.1% (+67 bps). Score 48 of 100, In line with trend. EBITDA margin rose 67 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.7% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹673 cr (+5% year on year), EBITDA ₹231 cr (+22% year on year), PAT ₹150 cr (+21% year on year), EBITDA margin 34.4% (+477 bps). Score 59 of 100, In line with trend. EBITDA margin rose 477 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +11.1% in 29 days (Nifty 500: +2.5%).
  • Q2 FY26: Revenue ₹588 cr, EBITDA ₹178 cr, PAT ₹130 cr, EBITDA margin 30.3%. Not scored. No result for the same quarter last year. Share price after the results: −0.8% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹602 cr, EBITDA ₹172 cr, PAT ₹122 cr, EBITDA margin 28.6%. Not scored. No result for the same quarter last year. Share price after the results: −5.6% in 28 days (Nifty 500: −0.9%).
  • Q4 FY25: Revenue ₹650 cr, EBITDA ₹198 cr, PAT ₹142 cr, EBITDA margin 30.5%. Not scored. No result for the same quarter last year. Share price after the results: −15.9% in 29 days (Nifty 500: +0.5%).
  • Q3 FY25: Revenue ₹642 cr, EBITDA ₹190 cr, PAT ₹137 cr, EBITDA margin 29.6%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Alivus Life Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.